9/8/21, 1:03 PM
A Breakthrough in Prostate Cancer Treatment | Todd Berner | Patient Advocacy
a
A Breakthrough in Prostate Cancer Treatment by Todd Berner | Sep 7, 2021 | Todd Berner
The American Cancer Society reports that 248,530 men contract prostate cancer every year in the United States alone. That results in more than 34,100 deaths. One in six men is at high risk to develop this form of cancer by age 85. In 2011, Johnson & Johnson introduced a new treatment for this disease branded and sold as Zytiga. Pharmacologists call it abiraterone acetate. It is designed to treat late-stage cases of prostate cancer in combination with prednisone, a common and widely used steroid medication. Zytiga quickly became a frontline treatment because of its demonstrated effectiveness in slowing down the rate at which prostate cancer develops. Now researchers at the University of South Australia (UniSA) say they have produced a significantly improved formulation of this life-saving prescription drug. Preliminary tests show the new Zytiga formulation is 40% more effective. The breakthrough was led by medical researcher Professor Clive Prestidge. He leads the Nanostructure and Drug Delivery Group at UniSA. He said the new drug takes advantage of an oil-based formulation that is taken orally. It allows for smaller doses of Zytiga that, in turn, will have the effect of reducing side effects, such as diarrhea and swelling of the joints. https://toddberner.com/a-breakthrough-in-prostate-cancer-treatment/
1/2